Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ACE inhibitors: future perspectives

¹Department of Medicine and Therapeutics, University of Glasgow, Glasgow, Scotland.

Journal of Cardiovascular Pharmacology

|January 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.

Hypertension (Dallas, Tex. : 1979)·1995

Same author

Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.

Arteriosclerosis, thrombosis, and vascular biology·1995

Same author

Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.

Journal of human hypertension·1995

Same author

Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

Annals of the New York Academy of Sciences·1995

Same author

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.

Journal of human hypertension·1995

Same author

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.

Journal of cardiovascular pharmacology·1995

Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026

Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026

Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026

Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026

Same journal

The Therapeutic Role of Exercise in Diabetic Cardiomyopathy: Underlying Mechanisms and Interactions with Antidiabetic Medications.

Journal of cardiovascular pharmacology·2026

Same journal

Cardiovascular Adverse Events Associated with Immune Checkpoint Inhibitors from the Perspective of Gut Microecology: Potential Roles and Research Advances of the Gut Microbiota.

Journal of cardiovascular pharmacology·2026

See all related articles

Chemical variations in angiotensin-converting enzyme (ACE) inhibitors affect how they work and how the body processes them. These differences impact drug effectiveness, side effects, and potential tissue-specific actions, guiding clinical use.

Area of Science:

Pharmacology
Cardiovascular Medicine
Nephrology

Background:

Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs with diverse chemical structures.
These structural variations lead to significant differences in their pharmacokinetic and pharmacodynamic profiles.

Purpose of the Study:

To explore the chemical distinctions among ACE inhibitors.
To understand how these differences influence drug behavior in the body and potential clinical applications.

Main Methods:

Comparative analysis of ACE inhibitor chemical properties.
Review of pharmacokinetic and pharmacodynamic data.
Assessment of tissue-specific ACE inhibition.

Main Results:

Related Experiment Videos

Identified variations in potency, affinity, and duration of action among ACE inhibitors.
Demonstrated that drug-target binding characteristics influence hemodynamic effects and adverse events like hypotension and renal impairment.
Highlighted the significance of differential tissue ACE inhibition.

Conclusions:

Chemical differences among ACE inhibitors are critical determinants of their clinical profiles.
Understanding these variations is essential for selecting appropriate ACE inhibitors for specific patient conditions.
Tissue-specific effects may guide the choice of ACE inhibitor for particular indications.